CNS DLBCL patients without PIM1 and CD79B mutations had inferior long-term survival after HD-MTX-based chemoimmunotherapy in the present study, even though they were younger and had a lower MCD subtype. Here, CD79B is linked to diffuse large B-cell lymphoma of the central nervous system.